Fundraising Fox
GENEOS Therapeutics
Plymouth Meeting, US · Delaware corporation · 12 employees on LinkedIn · 1 known investors
Find your way into GENEOS Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
481 people can intro you to Niranjan
Ask Thomas Kim to introduce you to Niranjan Y. Sardesai
You →Thomas · together at Inovio Pharmaceuticals, Inc. →Niranjan
Sign up to find every way you can get introduced to GENEOS Therapeutics
- Your email: who you already know at GENEOS Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the GENEOS Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
NY
Niranjan Y. SardesaiFounderNiranjan Y. Sardesai is an executive and director at GENEOS Therapeutics with experience in product development, R&D, and commercialization in biopharmaceuticals and diagnostics, including work on vaccines and therapeutics for infectious diseases and oncology. He holds multiple patents and has published numerous peer-reviewed articles in the life sciences field.
LH
Laurent HumeauNamed on SEC filing
JE
James EadieNamed on SEC filing
SB
Samuel BroderNamed on SEC filing
SL
Sangwoo LeeNamed on SEC filing
CC
Casey CunninghamNamed on SEC filing
TF
Ted FjallmanNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$37.1M disclosed across 4 rounds · 2019–2023
▶$5MraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurent HumeauDirector
- James EadieDirector
- Niranjan Y. SardesaiExecutive Officer, Director
- Samuel BroderDirector
- Sangwoo LeeDirector
- Casey CunninghamDirector
- Ted FjallmanDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.2MraisedMar 2022 · 9 investors · BiotechnologyRule 506(b)
▶$17.2MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph KimDirector
- Samuel BroderDirector
- Sangwoo LeeDirector
- Ted FjallmanDirector
- Niranjan SardesaiExecutive Officer, Director
- Eadie JamesDirector
- Casey CunninghamDirector
- Offering amount
- $25M
- Amount sold
- $17.2M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.4MraisedNov 2020 · 4 investors · BiotechnologyRule 506(b)
▶$10.4MraisedNov 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James EadieDirector
- J. Joseph KimDirector
- Casey CunninghamDirector
- Samuel BroderDirector
- Niranjan Y. SardesaiExecutive Officer, Director
- Sangwoo LeeDirector
- Offering amount
- $12M
- Amount sold
- $10.4M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$4.5MraisedFeb 2019 · 3 investors · BiotechnologyRule 506(b)
▶$4.5MraisedFeb 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- J. Joseph KimDirector
- Casey CunninghamDirector
- James EadieDirector
- Samuel Dr. BroderDirector
- Niranjan Y. SardesaiExecutive Officer, Director
- Offering amount
- $10.5M
- Amount sold
- $4.5M
- Sales commissions
- $50K
- Placement agents
- CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), M.M. Dillon & Co., LLC, CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets)
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded GENEOS Therapeutics?
- GENEOS Therapeutics was founded by Niranjan Y. Sardesai.
- Who are GENEOS Therapeutics's investors?
- GENEOS Therapeutics's investors include 3B Future Health Fund.
- How much funding has GENEOS Therapeutics raised?
- GENEOS Therapeutics has disclosed $37.1M raised across 4 rounds.
- Where is GENEOS Therapeutics headquartered?
- GENEOS Therapeutics is headquartered in Plymouth Meeting, US.